seraxis

Developing a cell therapy to treat insulin dependent diabetes

Press Release
4-8-13

Cell Therapy Start-Up Seraxis Secures Series A Funding

The cell therapy company, Seraxis Pte Ltd, has completed its Series A funding and begun operations. Seraxis uses proprietary cell culture technology to develop cell therapies to treat insulin-dependent diabetes. This start-up is headquartered in Singapore with a subsidiary, Seraxis Inc., in Germantown, Maryland USA. The multi-million dollar funding round was led in part by East West Capital Partners, a global life sciences and healthcare Private Equity firm headquartered out of Singapore, and included US-based investment firms GRI Fund, ASAP Ventures, and prominent Angel Investors. The company also has support from the foundation Dads Against Diabetes.

The US Subsidiary is a new tenant of the Germantown Innovation Center, a business incubator program of the Montgomery County Department of Economic Development Business Innovation Network. “We are extremely pleased to have Seraxis join our portfolio of companies,” said John Korpela, Director of the Business Innovation Network.

For more information and contact, visit www.seraxis.com.

SOURCE: Seraxis, Inc